FDA panel to discuss Immunomedics agent
A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the
A Food and Drug Administration advisory committee is set to meet
Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent
for colorectal cancer developed by Immunomedics. Immunomedics,
of Morris Plains, NJ, has been working with the FDA on the agent's
product license application (PLA) since the agency said the PLA
was not approvable in 1994 (SCAN 6/1/94).
Recent Videos
Related Content
